Interesting article on a fentanyl (Subsys) scam that’s worth a read if you have time. There is substantial focus on fentanyl right now, and I get a lot of questions from potential partners (especially payer-side) on the topic. This kind of “pill-mill” and pay-for-prescribing behavior drives focus and decision-making for payers and for regulators. A slightly different angle on the opioid challenge. The “higher commission for higher dose” is particularly horrifying.